

Ketosis-Prone Type 2 Diabetes

Time to revise the classification of diabetes

Diabetic ketoacidosis (DKA) is the most serious hyperglycemic emergency in patients with diabetes. DKA is reported to be responsible for >100,000 hospital admissions per year in the U.S. (1) and is present in 25–40% of children and adolescents with newly diagnosed diabetes (2) and in 4–9% of all hospital discharge summaries among adult patients with diabetes (3,4). DKA has long been considered a key clinical feature of type 1 diabetes, an autoimmune disorder characterized by severe and irreversible insulin deficiency. In recent years, however, an increasing number of ketoacidosis cases without precipitating cause have also been reported in children, adolescents, and adult subjects with type 2 diabetes (5–7). These subjects are usually obese and have a strong family history of diabetes and a low prevalence of autoimmune markers. At presentation, they have impairment of both insulin secretion and insulin action, but aggressive diabetes management results in significant improvement in β -cell function and insulin sensitivity sufficient to allow discontinuation of insulin therapy within a few months of treatment (7–9). Upon discontinuation of insulin, the period of near-normoglycemic remission may last for a few months to several years (10–13). This clinical presentation has been reported primarily in Africans and African Americans (6,7,14–16) and also in other minority ethnic groups (12,17,18). This variant of type 2 diabetes has been referred to in the literature as idiopathic type 1 diabetes, atypical diabetes, Flatbush diabetes, diabetes type 1 (1/2) (somewhere between type 1 and type 2 diabetes), and more recently as ketosis-prone type 2 diabetes (9).

In this issue of *Diabetes Care*, Balasubramayam et al. (19) compared the accuracy of four published classification schemes that have attempted to predict long-term β -cell function and insulin independence in patients with DKA. Each of these classification schemes takes into consideration the clinical features, body weight, insulin secretion, and presence of autoimmune markers of β -cell destruction (7,8,12,20). These investigators analyzed data from 294 consecutive patients

with DKA (45% African American, 40% Hispanic, 14% Caucasian, and 1% Asian) who were followed for a mean duration of 31 months (range 12–60 months) after an episode of DKA. β -Cell function was determined within 2 weeks of resolution of the index DKA episode and after 6–12 months. Positive β -cell function was defined by a fasting C-peptide >1.0 ng/ml or a peak C-peptide response >1.5 ng/ml after glucagon stimulation test (1 mg i.v.). β -Cell autoantibodies (glutamic acid decarboxylase [GAD] and IA-2) were measured shortly after presentation. They proposed a new A β classification scheme based on the presence or absence of β -cell autoantibodies and the β -cell function to predict whether patients with DKA will have preserved β -cell function and long-term insulin independence. The proposed A β classification scheme divided patients with DKA into four groups. Patients with autoimmune disease with absent (A+ β -) or preserved (A+ β +) β -cell function and those without autoimmune diabetes with absent (A- β -) or preserved (A- β +) β -cell function. This classification was found to have a sensitivity of 99.4%, specificity of 95.9%, positive predictive value of 97.1%, and negative predictive value of 99.2% in predicting whether patients with DKA will have preserved β -cell function and long-term insulin independence. The high predictive value was driven mainly by the presence of β -cell function following the resolution of DKA rather than the presence of autoimmune markers. Patients with negative β -cell function, with or without autoimmune markers, have clinical and biochemical characteristics of type 1 diabetes, i.e., they require exogenous insulin to preserve life (12). Less than 1% of the subjects classified initially as β - showed improvement in β -cell function during follow-up.

Patients with β -cell function despite autoimmune markers (A+ β +) represent 7% of newly diagnosed patients with DKA. Some A+ β + patients have long-term preservation of β -cell function, but about half of them follow a clinical course that resembles type 1 diabetes, with progressive deterioration of β -cell function, and require exogenous insulin therapy

(12). At presentation, A+ β + subjects have been shown to have lower basal and stimulated insulin secretion than those without antibodies (A- β +) and are more likely to relapse into hyperglycemia (21,22). These subjects could be classified as having latent autoimmune diabetes of the adult (23–26) or slowly progressing type 1 diabetes (27,28). During follow-up, most patients with latent autoimmune diabetes display features of insulin dependence including propensity toward developing ketosis and complete β -cell failure (24,29).

The group of major interest includes those patients without autoimmunity but preserved β -cell function (A- β +) . They represent 74% of adult patients with newly diagnosed diabetes presenting with DKA. Despite the presentation with severe metabolic decompensation, most patients showed clinical and biochemical characteristics of type 2 diabetes. Most A- β + subjects had new-onset diabetes and were obese, middle-aged males with a strong family history of type 2 diabetes. In these patients, β -cell function is substantial when measured within 1–2 weeks of the index DKA and improves further when measured after 6–12 months (12). Several observational and prospective studies have reported that ~70% of such patients achieve near-normoglycemia remission within 10 weeks of follow-up (7,8,10) and that 40% of patients remained free of insulin injections 10 years after their first presentation (8).

The proposed A β classification has the disadvantage of requiring repeated measurements of glucagon-stimulated insulin secretion, which is costly and not easily accessible in clinical practice. The evaluation of insulin secretion in patients with diabetes is difficult and is complicated by the effect of hyperglycemia per se on insulin secretion (30,31). Characteristically, first-phase insulin secretory responses to an oral or intravenous glucose tolerance test are lost in patients with established diabetes and plasma glucose >140 mg/dl (32). In contrast, β -cell response to nonglucose secretagogues (e.g., glucagon, arginine, and β -adrenergic agonists) is often preserved in the presence of hyperglycemia (7,33). Among

nonglucose secretagogues, glucagon stimulation is most commonly used because this test is easy to use and provides a rapid and accurate determination of β -cell function in patients with recent episodes of hyperglycemia (8,12,14,34,35). For this test, C-peptide levels are measured before and within 10 min after the intravenous administration of glucagon (1 mg) (6,7,10). In agreement with this report, fasting C-peptide levels >1.0 ng/dl (0.33 nmol/l) and stimulated C-peptide levels >1.5 ng/dl (0.5 nmol/l) shortly after presentation is predictive of long-term remission (6–8,10,12,14,36,37). Recent evidence suggests that a fasting C-peptide >1.0 ng/dl (0.33 nmol/l) within 2 weeks of presentation correlates well with the glucagon-stimulated C-peptide response in predicting long-term normoglycemic remission in subjects with a history of DKA (6–8,10,12,14,36,37).

The current classification and diagnosis of diabetes was developed by the National Diabetes Data Group (NDDG) of the U.S. in 1979 (38) and the second World Health Organization (WHO) Expert Committee on Diabetes in 1980 (39). Parallel international expert committees working under the sponsorship of the American Diabetes Association (ADA) and the WHO Consultation Committee proposed changes to the NDDG/WHO classification scheme in 1997 (40,41). The revised classification included type 1, with β -cell destruction and prone to ketoacidosis, type 2 that results from insulin resistance and relative (rather than absolute) insulin deficiency, gestational diabetes, and other types where the cause is associated with monogenetic defects in β -cell function, endocrinopathies, disorders of exocrine pancreas, drug- or chemical-induced diabetes, and other rare immune-mediated or genetic syndromes sometimes associated with diabetes. Patients with DKA are classified as having type 1a (autoimmune) or type 1b (idiopathic or nonautoimmune) diabetes. Type 1B or idiopathic diabetes includes patients prone to develop ketoacidosis with varying degrees of insulin deficiency, no evidence of autoimmunity, and in whom “an absolute requirement for insulin replacement therapy in affected patients may come and go” (20). The information presented by Balasubramayam et al. (19) indicates that despite the presentation with ketoacidosis, most patients with “idiopathic” diabetes have type 2 diabetes. In such patients, determi-

nation of autoimmune markers and measurement of basal or stimulated C-peptide levels shortly after admission predicts long-term β -cell function and long-term insulin independence.

Patients with ketosis-prone type 2 diabetes were once described as having “atypical diabetes;” however, increasing evidence indicates that this subtype of diabetes accounts for more than half of newly diagnosed black and Hispanic patients with DKA (3,6,17,42,43). These subjects are usually obese, have a strong family history of diabetes, have a low prevalence of autoimmune markers, and lack HLA genetic association (9). Most patients with ketosis-prone diabetes are able to discontinue insulin therapy within a few months of treatment. Thus, a newly diagnosed patient with ketoacidosis, in particular if overweight/obese from a minority ethnic group, is more likely to show clinical and immunologic features of type 2 rather than type 1 diabetes during follow-up. These data indicate that the current ADA/WHO classification should be revised to reclassify patients with idiopathic or type 1B diabetes as having “ketosis-prone type 2 diabetes.”

GUILLERMO E. UMPIERREZ, MD, FACP, FACE

From the Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.

Address correspondence to Guillermo Umpierrez, MD, Associate Professor of Medicine, Associate Director, General Clinical Research Center, Emory University School of Medicine, 49 Jesse Hill Jr. Dr., Atlanta, GA 30303. E-mail: geumpie@emory.edu.

Received for publication 7 September 2006 and accepted 8 September 2006.

DOI: 10.2337/dc06-1870

© 2006 by the American Diabetes Association.

Acknowledgments—Dr. Umpierrez is supported by research grants from the American Diabetes Association (7-03-CR-35), American Heart Association (0555306B), and National Institutes of Health: R03 DK073190-01 and General Clinical Research Center Grant M01 RR-00039.

References

- Fishbein HA, Palumbo PJ: Acute metabolic complications in Diabetes. In *Diabetes in America*. National Diabetes Data Group, National Institutes of Health, 1995, p. 283–291 (NIH publ. no. 95-1468).
- Smith CP, Firth D, Bennett S, Howard C, Chisholm P: Ketoacidosis occurring in newly diagnosed and established diabetic children. *Acta Paediatr* 87:537–541, 1998
- Faich GA, Fishbein HA, Ellis SE: The ep-

idemiology of diabetic acidosis: a population-based study. *Am J Epidemiol* 117:551–558, 1983

- Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE: Hyperglycemic crises in urban blacks. *Arch Intern Med* 157:669–675, 1997
- Type 2 diabetes in children and adolescents: American Diabetes Association. *Pediatrics* 105:671–680, 2000
- Umpierrez GE, Woo W, Hagopian WA, Isaacs SD, Palmer JP, Gaur LK, Nepom GT, Clark WS, Mixon PS, Kitabchi AE: Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. *Diabetes Care* 22:1517–1523, 1999
- Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS: Diabetic ketoacidosis in obese African-Americans. *Diabetologia* 44:790–795, 1995
- Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, Charpentier G, Guillausseau PJ, Vexiau P, Gautier JF: Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of β -cell dysfunction and insulin resistance. *Diabetes* 53:645–653, 2004
- Umpierrez GE, Smiley D, Kitabchi AE: Narrative review: ketosis-prone type 2 diabetes mellitus. *Ann Intern Med* 144:350–357, 2006
- Umpierrez GE, Clark WS, Steen MT: Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. *Diabetes Care* 20:479–483, 1997
- Banerji MA, Chaiken RL, Lebovitz HE: Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. *Diabetes* 45:337–341, 1996
- Maldonado M, Hampe CS, Gaur LK, D’Amico S, Iyer D, Hammerle LP, Bolgiano D, Rodriguez L, Rajan A, Lernmark A, Balasubramanyam A: Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. *J Clin Endocrinol Metab* 88:5090–5098, 2003
- Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF: Diabetes in Africans. Part 2: Ketosis-prone atypical diabetes mellitus. *Diabetologia* 28:5–12, 2002
- Sobngwi E, Vexiau P, Levy V, Lepage V, Mauvais-Jarvis F, Leblanc H, Mbanya JC, Gautier JF: Metabolic and immunogenetic prediction of long-term insulin remission in African patients with atypical diabetes. *Diabet Med* 19:832–835, 2002
- Banerji MA, Chaiken RL, Huey H, Tuomi T, Norin AJ, Mackay IR, Rowley MJ, Zimmet PZ, Lebovitz HE: GAD antibody negative NIDDM in adult black subjects with diabetic ketoacidosis and increased fre-

- quency of human leukocyte antigen DR3 and DR4: Flatbush diabetes. *Diabetes* 43: 741–745, 1994
16. Kitabchi AE: Ketosis-prone diabetes: a new subgroup of patients with atypical type 1 and type 2 diabetes? *J Clin Endocrinol Metab* 88:5087–5089, 2003
 17. Balasubramanyam A, Zern JW, Hyman DJ, Pavlik V: New profiles of diabetic ketoacidosis: type 1 vs type 2 diabetes and the effect of ethnicity. *Arch Intern Med* 159:2317–2322, 1999
 18. Yamada K, Nonaka K: Diabetic ketoacidosis in young obese Japanese men (Letter). *Diabetes Care* 19:671, 1996
 19. Balasubramanyam A, Garza G, Rodriguez LVN, Hampe CS, Gaur L, Lernmark Å, Maldonado MR: Accuracy and predictive value of classification schemes for ketosis-prone diabetes. *Diabetes Care* 29:2575–2579, 2006
 20. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 26 (Suppl. 1):S5–S20, 2003
 21. Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K: Time course of islet cell antibodies and β -cell function in non-insulin-dependent stage of type 1 diabetes. *Diabetes* 36:510–517, 1987
 22. Kobayashi T, Nakanishi K, Murase T, Kosaka K: Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β -cell failure in islet cell antibody-positive patients with clinical features of NIDDM. *Diabetes* 45:622–626, 1996
 23. Schiel R, Muller UA: GAD autoantibodies in a selection-free population of insulin-treated diabetic patients: indicator of a high prevalence of LADA? *Diabetes Res Clin Pract* 49:33–40, 2000
 24. Pozzilli P, Di Mario U: Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. *Diabetes Care* 24: 1460–1467, 2001
 25. Groop LC, Bottazzo GF, Doniach D: Islet cell antibodies identify latent type 1 diabetes in patients aged 35–75 years at diagnosis. *Diabetes* 35:237–241, 1986
 26. Hagopian WA, Karlson AE, Gottsater A, Landin-Olsson M, Grubin CE, Sundkvist G, Petersen JS, Boel E, Dyrberg T, Lernmark A: Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. *J Clin Invest* 91:368–374, 1993
 27. Zimmet P, Turner R, McCarty D, Rowley M, Mackay I: Crucial points at diagnosis: type 2 diabetes or slow type 1 diabetes. *Diabetes Care* 22 (Suppl. 2):B59–B64, 1999
 28. Kobayashi T: Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM: the clinical characteristics and pathogenesis of the syndrome. *Diabetes Res Clin Pract* 24 (Suppl.):S95–S99, 1994
 29. Borg H, Gottsater A, Fernlund P, Sundkvist G: A 12-year prospective study of the relationship between islet antibodies and β -cell function at and after the diagnosis in patients with adult-onset diabetes. *Diabetes* 51:1754–1762, 2002
 30. Robertson RP, Olson LK, Zhang HJ: Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. *Diabetes* 43:1085–1089, 1994
 31. Kahn SE: Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. *J Clin Endocrinol Metab* 86:4047–4058, 2001
 32. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM: a balanced overview. *Diabetes Care* 15:318–368, 1992
 33. Leahy JL: Natural history of β -cell dysfunction in NIDDM. *Diabetes Care* 13: 992–1010, 1990
 34. Maldonado MR, Otiniano ME, Lee R, Rodriguez L, Balasubramanyam A: Characteristics of ketosis-prone diabetes in a multiethnic indigent community. *Ethn Dis* 14:243–249, 2004
 35. Tan KC, Mackay IR, Zimmet PZ, Hawkins BR, Lam KS: Metabolic and immunologic features of Chinese patients with atypical diabetes. *Diabetes Care* 23:335–338, 2000
 36. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA: Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. *Diabet Med* 18:10–16, 2001
 37. Aguilera E, Casamitjana R, Ercilla G, Oriola J, Gomis R, Conget I: Adult-onset atypical (type 1) diabetes: additional insights and differences with type 1A diabetes in a European Mediterranean population. *Diabetes Care* 27:1108–1114, 2004
 38. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance: National Diabetes Data Group. *Diabetes* 28:1039–1057, 1979
 39. World Health Organization Expert Committee on Diabetes Mellitus: *Report of a WHO Study Group*. 2nd report. Geneva, World Health Org., 1980 (Tech. Rep. Ser., no. 646)
 40. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15:539–553, 1998
 41. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 20:1183–1197, 1997
 42. Banerji MA, Lebovitz HE: Remission in non-insulin-dependent diabetes mellitus: clinical characteristics of remission and relapse in black patients. *Medicine* 69: 176–185, 1990
 43. Pinero-Pilona A, Litonjua P, Aviles-Santa L, Raskin P: Idiopathic type 1 diabetes in Dallas, Texas: a 5-year experience. *Diabetes Care* 24:1014–1018, 2001